A common childhood surgical procedure may carry an underappreciated neurological consequence — one that challenges the assumption that adenotonsillectomy is a straightforward, low-risk intervention. For families and clinicians weighing the decision to remove tonsils and adenoids, this finding introduces a dimension of risk that extends well beyond the operating room.
A multicenter case-control study enrolling 359 children with multiple sclerosis and 560 pediatric controls across 16 MS specialty clinics found that a prior adenotonsillectomy was associated with a 63% increased odds of developing pediatric-onset MS, after adjusting for confounders including EBV serostatus and the HLA-DRB1*15:01:01 allele — two of the strongest known genetic and infectious risk factors for MS. Among the 239 POMS patients with longitudinal follow-up data, the surgery was further linked to a twofold increase in annualized relapse rate, suggesting not merely elevated susceptibility but accelerated disease activity once MS develops.
The biological rationale centers on the known role of Epstein-Barr virus in MS pathogenesis. Tonsils and adenoids function as primary lymphoid reservoirs where EBV establishes latency; their surgical removal may disrupt immune surveillance mechanisms that normally contain viral activity or modulate EBV-specific T-cell responses. This aligns with emerging research implicating molecular mimicry between EBV antigens and myelin proteins as a trigger for central nervous system autoimmunity. The finding is biologically plausible and consistent with earlier smaller studies suggesting immune dysregulation following adenotonsillectomy.
Key limitations warrant caution: the study is observational, making reverse causation difficult to fully exclude — children prone to recurrent infections may have both higher EBV exposure and greater surgical rates. Sample sizes, while respectable for a rare pediatric disease, remain modest. This finding should be considered hypothesis-generating rather than definitive, but its clinical signal is strong enough to merit prospective validation and a re-examination of elective adenotonsillectomy counseling protocols.